Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Ocular Technologies

Ocular Technologies is a wholly owned Auven Therapeutics subsidiary through which all SecieraTM (OTX-101) rights are held. Seciera is a novel nanoscale micelle formulation of cyclosporine utilizing patent-protected proprietary technology developed by Auven Therapeutics, in cooperation with scientific collaborators, specifically to improve the ocular tissue penetration and tolerability of topical ophthalmic therapies. The micelles containing the active compound are composed entirely of inert materials and are on average less than 25 nanometers in diameter. Seciera is covered by patents until at least 2033. Unlike other ocular formulations of cyclosporine, Seciera is a clear, preservative-free, aqueous solution.

Ocular Technologies Headquarter Location

6501 Redhook Plaza Suite 201

St. Thomas, 00802,

Virgin Islands (U.S.)

340-779-6908

Latest Ocular Technologies News

Artificial intelligence is not free from bias

Sep 8, 2019

Weekend Argus  / 8 September 2019, 12:09pm / LUKE FOLB Neo, the female robot, with a programmable voice interface developed by Ocular Technologies was a highlight at the AI Expo this year which took place at the Century City Conference Centre. Courtney Africa African News Agency (ANA) Cape Town - Artificial intelligence (AI) is meant to be better and smarter than humans but it too can succumb to bias and a lack of ethics if it isn’t fed data to eliminate learnt human behaviour. Experts in ethics, privacy and bias in AI spoke at the AI Expo Africa conference held in Cape Town this week. Highlights included an AI art and music challenge, and French company Rhoban who showed off their soccer-playing robots. The robots are also the RoboWorld Cup champions. Mushambi Mutuma, chief executive at tech company Altivex said AI was controlled by the people who input the data. “Last year Google’s facial recognition software kept inputting African-Americans as gorillas. We have to have new voices and a bit more diversity because the data will never come back accurate and that’s what we’ve tried to solve from bias,” he said. Andrew Quixley works with data science and AI at IBM and said the company also struggled with bias in their AI programmes. “We were one of the companies that were caught out with AI that was not performing well with female faces and darker skin faces. “We have a bias detector and we have a product to find out why bias exists in a model,” he said. But Quixley said humans might not be ready to eliminate bias from AI in any case, adding: “Which person should die in a car accident in a car that was being driven autonomously? Out of 40 million human inputs the bias is clear. “We’d rather save someone who is law abiding, a female, has a higher income than the person in the other car. We need to say, do we want to be the same as humans or smarter than humans? We’re going to have to accept imperfection of some kind.” The price to pay for living in the digital age is having your data floating about in cyberspace susceptible to hacking or surveillance. This week, the City of Joburg announced plans to roll out a massive 15000-camera network that will capture the movements of residents. “You can anticipate the crimes you want to legislate for but it isn’t perfect. There’s a man in the UK that’s suing the court because he claims that the facial recognition software isn’t good enough for him to be convicted,” said Quixley. However, in a survey conducted by Genesys, it found that more than half of the employers that participated in the multi-country survey said their companies “do not currently have a written policy on the ethical use of AI or bots”. In the same survey 21% said they were concerned that their companies could use AI in an unethical manner. Rachel Alexander, founder of Omina Technologies, said companies should be ethical in how they use their AI because they could run into potential liable issues. Alexander said if an AI bot was being used to evaluate workers’ performance there could be potential problems that arose from a faulty one. “It could be that your algorithm is firing all the fat people in your company and you can’t explain your decision. Companies need to think about how they’re going to open up and explain how the decision-making is being done.” She said following guidelines for ethical AI was important and cited the EU’s guidelines as a good example. “I was fairly involved with EU guidelines and they put together a coalition with academics, start-up companies and lawyers as well and tried to reach a consensus about what the ethical guidelines and principles should be. “The EU is talking about augmented intelligence. They had a doctor diagnose cancer in a patient and AI diagnose cancer. Then the doctor and the AI diagnosed the patient together and the results came out better so they want it to be machine and human working together,” said Alexander. Many companies are pursuing the implementation of AI models in their business to streamline workflows and help employees eliminate mundane tasks from their work to use their time more productively. Weekend Argus

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ocular Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ocular Technologies is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

Ocular Technologies Patents

Ocular Technologies has filed 8 patents.

The 3 most popular patent topics include:

  • Antiandrogens
  • Diseases of the eye and adnexa
  • Ophthalmology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/12/2016

10/15/2019

Colloidal chemistry, Cytokines, G protein coupled receptors, Membrane biology, Ethers

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/12/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/15/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Colloidal chemistry, Cytokines, G protein coupled receptors, Membrane biology, Ethers

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.